Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Mycobacterial immunotherapy for prostate cancer: where can we go from here?

Stavrinides, V; Dalgleish, A; Copier, JP; Moore, CM (2020) Mycobacterial immunotherapy for prostate cancer: where can we go from here? Nat Rev Urol, 17 (4). pp. 189-190. ISSN 1759-4820
SGUL Authors: Dalgleish, Angus George

[img] PDF Accepted Version
Restricted to Repository staff only until 29 July 2020.
Available under License ["licenses_description_publisher" not defined].

Download (114kB)


The effects of mycobacteria in prostate cancer have not been fully elucidated. Results of early studies indicated that mycobacterial immunotherapy conferred a survival benefit in patients with advanced prostate cancer, and recent evidence supports the safety and efficacy of new mycobacterial agents in many malignancies; thus, modern, carefully designed, randomized controlled trials of mycobacterial immunotherapy for prostate cancer could be warranted.

Item Type: Article
Additional Information: This is a post-peer-review, pre-copyedit version of an article published in Nature Reviews Urology. The final authenticated version is available online at:
Keywords: 1103 Clinical Sciences, Urology & Nephrology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Nat Rev Urol
ISSN: 1759-4820
Language: eng
April 2020Published
29 January 2020Published Online
8 January 2020Accepted
Publisher License: Publisher's own licence
Project IDFunderFunder ID
164271Institute for Cancer Vaccines and ImmunotherapyUNSPECIFIED
MR/S005897/1Medical Research Council
PubMed ID: 31996816
Go to PubMed abstract
Publisher's version:

Actions (login required)

Edit Item Edit Item